Is ABEO or DMRA more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Does the media prefer PAHC or ABEO?

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Phibro Animal Health's average media sentiment score of 1.40 beat Abeona Therapeutics' score of 0.94 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ABEO or AKTS?

Abeona Therapeutics has higher revenue and earnings than Aktis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abeona Therapeutics $14.54M 22.19 $71.18M $0.97 5.84 Aktis Oncology $6.50M 247.94 -$63.73M N/A N/A

Is ABEO or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Aktis Oncology N/A N/A N/A

Does the media favor ABEO or AKTS?

In the previous week, Aktis Oncology had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.94 beat Aktis Oncology's score of 0.62 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MPLT or ABEO more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Abeona Therapeutics N/A -53.98% -38.52%

Does the media favor MPLT or ABEO?

In the previous week, Maplight Therapeutics had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.41 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Abeona Therapeutics (ABEO) Competitors

$5.66 +0.05 (+0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$5.63 -0.03 (-0.51%)

As of 04:43 PM Eastern

Compare

ABEO vs. IMTX, DMRA, PAHC, AKTS, and MPLT

Should you buy Abeona Therapeutics stock or one of its competitors? MarketBeat compares Abeona Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abeona Therapeutics include Immatics (IMTX), Damora Therapeutics, Inc. Common Stock (DMRA), Phibro Animal Health (PAHC), Aktis Oncology (AKTS), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Abeona Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Immatics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Abeona Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Abeona Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Abeona Therapeutics' score of 0.94 indicating that Immatics is being referred to more favorably in the media.

Company	Overall Sentiment
Immatics	Very Positive
Abeona Therapeutics	Positive

Immatics presently has a consensus price target of $20.80, suggesting a potential upside of 117.69%. Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 235.63%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abeona Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	23.46	-$222.26M	-$1.99	N/A
Abeona Therapeutics	$14.54M	22.19	$71.18M	$0.97	5.84

Summary

Abeona Therapeutics beats Immatics on 10 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Abeona Therapeutics (NASDAQ:ABEO) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 235.63%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $42.43, indicating a potential upside of 77.01%. Given Abeona Therapeutics' higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Abeona Therapeutics had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 2 mentions for Abeona Therapeutics and 1 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.89 beat Abeona Therapeutics' score of 0.94 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
Abeona Therapeutics	Positive
Damora Therapeutics, Inc. Common Stock	Very Positive

Abeona Therapeutics has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$14.54M	22.19	$71.18M	$0.97	5.84
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

Abeona Therapeutics' return on equity of -53.98% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Summary

Abeona Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Phibro Animal Health has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Abeona Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Abeona Therapeutics	N/A	-53.98%	-38.52%

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abeona Therapeutics has lower revenue, but higher earnings than Phibro Animal Health. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.86	$48.26M	$2.33	13.67
Abeona Therapeutics	$14.54M	22.19	$71.18M	$0.97	5.84

Phibro Animal Health presently has a consensus target price of $42.50, indicating a potential upside of 33.48%. Abeona Therapeutics has a consensus target price of $19.00, indicating a potential upside of 235.63%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Phibro Animal Health's average media sentiment score of 1.40 beat Abeona Therapeutics' score of 0.94 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Phibro Animal Health beats Abeona Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Aktis Oncology?

Abeona Therapeutics (NASDAQ:ABEO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Abeona Therapeutics has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$14.54M	22.19	$71.18M	$0.97	5.84
Aktis Oncology	$6.50M	247.94	-$63.73M	N/A	N/A

Aktis Oncology's return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Aktis Oncology	N/A	N/A	N/A

Abeona Therapeutics currently has a consensus target price of $19.00, suggesting a potential upside of 235.63%. Aktis Oncology has a consensus target price of $34.00, suggesting a potential upside of 12.66%. Given Abeona Therapeutics' higher probable upside, equities research analysts clearly believe Abeona Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aktis Oncology had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 4 mentions for Aktis Oncology and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.94 beat Aktis Oncology's score of 0.62 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aktis Oncology beats Abeona Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Abeona Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Maplight Therapeutics currently has a consensus target price of $38.80, suggesting a potential upside of 12.89%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 235.63%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Maplight Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Abeona Therapeutics	N/A	-53.98%	-38.52%

80.6% of Abeona Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Abeona Therapeutics	$14.54M	22.19	$71.18M	$0.97	5.84

In the previous week, Maplight Therapeutics had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 8 mentions for Maplight Therapeutics and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.94 beat Maplight Therapeutics' score of 0.41 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abeona Therapeutics beats Maplight Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$322.65M	$3.66B	$6.85B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	5.84	21.26	25.82	24.36
Price / Sales	22.19	344.09	549.91	101.32
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	1.93	8.71	10.97	6.50
Net Income	$71.18M	$23.92M	$3.58B	$336.61M
7 Day Performance	-1.55%	4.16%	3.00%	0.89%
1 Month Performance	-2.06%	1.64%	0.67%	-0.36%
1 Year Performance	-1.55%	69.77%	36.72%	31.12%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	3.0466 of 5 stars	$5.66 +0.9%	$19.00 +235.7%	-2.3%	$322.59M	$14.54M	5.84	90	Positive News
IMTX Immatics	2.7347 of 5 stars	$9.78 flat	$20.80 +112.7%	+75.3%	$1.31B	$54.60M	N/A	260	Positive News
DMRA Damora Therapeutics, Inc. Common Stock	3.8474 of 5 stars	$23.89 +12.5%	$42.43 +77.6%	+652.3%	$1.31B	N/A	N/A	40	Positive News
PAHC Phibro Animal Health	4.8327 of 5 stars	$31.07 -2.4%	$42.50 +36.8%	+23.5%	$1.29B	$1.50B	13.33	2,475	Positive News Upcoming Earnings
AKTS Aktis Oncology	1.0107 of 5 stars	$24.79 +2.9%	$34.00 +37.2%	N/A	$1.29B	$6.50M	N/A	76

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. IMTX, DMRA, PAHC, AKTS, and MPLT

How does Abeona Therapeutics compare to Immatics?

Summary

How does Abeona Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Abeona Therapeutics compare to Phibro Animal Health?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Summary

How does Abeona Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. IMTX, DMRA, PAHC, AKTS, and MPLT

How does Abeona Therapeutics compare to Immatics?

Which has more volatility and risk, IMTX or ABEO?

Do institutionals & insiders hold more shares of IMTX or ABEO?

Does the media prefer IMTX or ABEO?

Do analysts recommend IMTX or ABEO?

Is IMTX or ABEO more profitable?

Which has higher valuation and earnings, IMTX or ABEO?

Summary

How does Abeona Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Do analysts prefer ABEO or DMRA?

Does the media refer more to ABEO or DMRA?

Which has higher valuation and earnings, ABEO or DMRA?

Is ABEO or DMRA more profitable?

Do insiders and institutionals hold more shares of ABEO or DMRA?

Which has more risk & volatility, ABEO or DMRA?

Summary

How does Abeona Therapeutics compare to Phibro Animal Health?

Which has more volatility & risk, PAHC or ABEO?

Is PAHC or ABEO more profitable?

Do institutionals and insiders believe in PAHC or ABEO?

Which has better valuation and earnings, PAHC or ABEO?

Do analysts recommend PAHC or ABEO?

Does the media prefer PAHC or ABEO?

Summary

How does Abeona Therapeutics compare to Aktis Oncology?

Which has preferable valuation & earnings, ABEO or AKTS?

Is ABEO or AKTS more profitable?

Do analysts rate ABEO or AKTS?

Do institutionals & insiders hold more shares of ABEO or AKTS?

Does the media favor ABEO or AKTS?

Summary

How does Abeona Therapeutics compare to Maplight Therapeutics?

Do analysts prefer MPLT or ABEO?

Is MPLT or ABEO more profitable?

Do insiders & institutionals hold more shares of MPLT or ABEO?

Which has better valuation and earnings, MPLT or ABEO?

Does the media favor MPLT or ABEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools